Jove
Visualize
Contact Us

Related Concept Videos

Acute Pyelonephritis II: Diagnostic Studies and Management01:28

Acute Pyelonephritis II: Diagnostic Studies and Management

200
Introduction:For diagnosing acute pyelonephritis, a comprehensive patient history is collected to identify symptoms such as dysuria, frequent or urgent urination, flank pain, or costovertebral angle (CVA) tenderness that may suggest a kidney infection.Physical ExaminationDuring the physical examination, CVA tenderness is assessed. This involves gentle percussion over the costovertebral angle, where tenderness often indicates a kidney infection.Diagnostic TestsUrinalysis: Used to identify white...
200
Healthcare Associated Infections II: Preventive Measures01:22

Healthcare Associated Infections II: Preventive Measures

3.5K
Essential infection prevention measures are based on the knowledge of the infection chain, the modes of transmission in healthcare settings, and the use of the best practices in all healthcare settings. Compulsory public reporting of healthcare-associated infection rates is needed to allow individuals and the community to make informed choices regarding selecting a healthcare facility.
The best practices for preventing healthcare-associated infections include hand hygiene, patient risk...
3.5K
Infection01:20

Infection

11.4K
When a pathogen enters the body and reproduces, it can cause an infection, damage body cells, and cause illness symptoms that eventually lead to disease. Therefore, its prevention requires breaking the chain of infection.
The chain begins with pathogens: bacteria, viruses, fungi, prions, or parasites such as protozoa helminths. These can be present on the skin as transient or resident flora, or they can be acquired from the environment. Identifying and treating the type of infection and...
11.4K
Pneumonia IV: Management01:28

Pneumonia IV: Management

662
The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
662
Urinary Tract Infection IV: Nursing Management01:17

Urinary Tract Infection IV: Nursing Management

314
In managing urinary tract infections (UTIs) in nursing, a comprehensive assessment is essential. Begin by gathering subjective data, such as the patient’s complaints of dysuria (painful urination), urinary frequency, urgency, suprapubic pain, and any lower abdominal discomfort. This information can be complemented by questions regarding previous UTIs, sexual activity, and personal hygiene practices, which can provide insight into risk factors. Objective assessment should focus on signs...
314
Parentral Nutrition: Centeral and Peripheral Parental Nutrition01:27

Parentral Nutrition: Centeral and Peripheral Parental Nutrition

551
Parenteral Nutrition (PN) delivers essential nutrients directly into the bloodstream, bypassing the digestive system. It is commonly used for individuals with severe digestive disorders or conditions that prevent normal nutrient absorption.
PN can be administered through two primary routes:
1. Central Parenteral Nutrition (CPN):
CPN involves delivering a high concentration of nutrients through a large vein. This is typically achieved using a Peripherally Inserted Central Catheter (PICC) or,...
551

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Targeted peri-operative prophylaxis in patients colonized with Carbapenem Resistant Enterobacterales undergoing Liver Transplantation: a multinational cohort study.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America·2026
Same author

Donors Infectious Risk Stratification: Activity of the Italian National Transplant Center.

Transplant infectious disease : an official journal of the Transplantation Society·2025
Same author

Post-COVID-19 Syndrome as Described by Patients: A Qualitative Study.

Healthcare (Basel, Switzerland)·2025
Same author

SARS-CoV-2 and influenza vaccine hesitancy during the COVID-19 pandemic in a dynamic perspective.

Human vaccines & immunotherapeutics·2024
Same author

<i>Pseudomonas aeruginosa</i> Bloodstream Infections Presenting with Septic Shock in Neutropenic Cancer Patients: Impact of Empirical Antibiotic Therapy.

Microorganisms·2024
Same author

Post-COVID-19 Syndrome 2 Years After the First Wave: The Role of Humoral Response, Vaccination and Reinfection.

Open forum infectious diseases·2023
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: Dec 19, 2025

Author Spotlight: Advancements in Retroperitoneal Approach for Necrotizing Pancreatitis
03:42

Author Spotlight: Advancements in Retroperitoneal Approach for Necrotizing Pancreatitis

Published on: March 15, 2024

974

How to manage KPC infections.

Matteo Bassetti1, Maddalena Peghin2

  • 1Clinica Malattie Infettive, Azienda Ospedaliero-Universitaria "Santa Maria della Misericordia", Piazzale S. Maria della Misericordia, n. 15, Udine, 33100, Italy.

Therapeutic Advances in Infectious Disease
|June 4, 2020
PubMed
Summary

Carbapenemase-producing Enterobacteriaceae, especially Klebsiella pneumoniae carbapenemase (KPC)-producing K. pneumoniae (KPC-KP), pose a growing global health risk. This review discusses challenges in KPC-KP infection management and treatment, highlighting limited options and the need for new antimicrobials.

Keywords:
KPCKPC-KPKlebsiella pneumoniae carbapenemase producing K. pneumoniaeMDR-GNBcarbapenem-resistant Enterobacteriaceaemultidrug-resistant Gram-negativenew antibiotics

More Related Videos

Ultrasound-Guided Orthotopic Implantation of Murine Pancreatic Ductal Adenocarcinoma
06:21

Ultrasound-Guided Orthotopic Implantation of Murine Pancreatic Ductal Adenocarcinoma

Published on: November 19, 2019

11.9K

Related Experiment Videos

Last Updated: Dec 19, 2025

Author Spotlight: Advancements in Retroperitoneal Approach for Necrotizing Pancreatitis
03:42

Author Spotlight: Advancements in Retroperitoneal Approach for Necrotizing Pancreatitis

Published on: March 15, 2024

974
Ultrasound-Guided Orthotopic Implantation of Murine Pancreatic Ductal Adenocarcinoma
06:21

Ultrasound-Guided Orthotopic Implantation of Murine Pancreatic Ductal Adenocarcinoma

Published on: November 19, 2019

11.9K

Area of Science:

  • Clinical microbiology and infectious diseases
  • Antimicrobial resistance
  • Pharmacology

Background:

  • Carbapenemase-producing Enterobacteriaceae (CPE) are a significant global health threat.
  • Klebsiella pneumoniae carbapenemase (KPC)-producing K. pneumoniae (KPC-KP) is a major contemporary pathogen, particularly in endemic regions.
  • Effective management of KPC-KP infections is challenged by limited therapeutic options and emerging resistance.

Purpose of the Study:

  • To review the challenges associated with the management and treatment of KPC-KP infections.
  • To provide an expert opinion on current and future therapeutic strategies for KPC-KP.
  • To emphasize the importance of individualized therapy based on patient factors and infection severity.

Main Methods:

  • Literature review focusing on KPC-KP epidemiology, diagnostics, and treatment.
  • Analysis of current therapeutic approaches, including combination therapies and emerging antimicrobials.
  • Discussion of pharmacokinetic/pharmacodynamic principles in relation to minimum inhibitory concentration (MIC).

Main Results:

  • Current treatment options for KPC-KP infections are limited, with combination therapies often yielding suboptimal results.
  • New antimicrobials targeting KPC-KP are in development, offering potential future treatment avenues.
  • Individualized treatment, risk stratification, and rapid diagnostics are crucial for effective patient management.

Conclusions:

  • Managing KPC-KP infections requires a multifaceted approach, including strict infection control measures.
  • Optimal use of new antimicrobials is essential to delay the emergence of further resistance.
  • Further research and development of novel therapeutic agents are critical to combat the growing threat of KPC-KP.